Validation of post‐treatment PET‐based dosimetry software for hepatic radioembolization of Yttrium‐90 microspheres

Abstract

Dose calculation results from MIM SurePlan were found to be in good agreement with our in-house algorithm. This indicates that MIM SurePlan performs as it should and, hence, can be deemed accepted and commissioned for clinical use for post-implant PET-based dosimetry of ⁹⁰ Y radioembolization.